Evidence map›Paper›PMID 32047294›Full record

ReviewNature reviews. Microbiology2020

Drug resistance and tolerance in fungi.

Judith Berman, Damian J Krysan

Erratum issuedAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 353 papers.

0numbers the graph read from it
0cells of the map it votes in
353citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

353 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Beyond roughness: Lateral surface architecture drives Candida albicans virulence on denture polymers.Dental materials : official publication of the Academy of Dental Materials · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Early Cellular Responses ofAntibiotics (Basel, Switzerland) · 2026
    Article
  13. Article
  14. Morphotype-specific susceptibility toMicrobiology spectrum · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

293 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Judith BermanSchool of Molecular Cell Biology & Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel. berma003@umn.edu.ORCID http://orcid.org/0000-0002-8577-0084
Damian J KrysanDepartment of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

Funding

Characterization of Activity and Mechanism of Novel Fungicidal Anti-Cryptococcal MoleculesR21AI125094 · NIAID · UNIVERSITY OF ROCHESTER · PI KRYSAN, DAMIAN J · 2016 to 2017
$421k
European Research Council 340087NIAID NIH HHS R21 AI125094
6 · The paper itself

Abstract

Systemic fungal infections pose a serious clinical problem. Treatment options are limited, and antifungal drug resistance is increasing. In addition, a substantial proportion of patients do not respond to therapy despite being infected with fungi that are susceptible to the drug. The discordance between overall treatment outcome and low levels of clinical resistance may be attributable to antifungal drug tolerance. In this Review, we define and distinguish resistance and tolerance and discuss the current understanding of the molecular, genetic and physiological mechanisms that contribute to those phenomena. Distinguishing tolerance from resistance might provide important insights into the reasons for treatment failure in some settings.

Indexed as

Drug Resistance, FungalAntifungal AgentsCandidaDrug ToleranceHumansMicrobial Sensitivity TestsAntifungal Agents

Identifiers

PMID32047294
PMCPMC7231573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.